• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002390.SZ
Share

Guizhou Xinbang Pharmaceutical Co., Ltd. Stocks

CN¥ 2.96Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 797.51M

CN¥ 2.96
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guizhou Xinbang Pharmaceutical Co., Ltd. specializes in the entire process of researching, developing, manufacturing, and distributing both traditional Chinese herbal medicines and cutting-edge biological pharmaceuticals. The company's operations span across China and international markets. Its diverse range of pharmaceutical offerings covers treatments for cardiovascular and cerebrovascular conditions, digestive system disorders, endocrine imbalances, tumor and immune regulation, blood system ailments, rheumatism and rheumatoid diseases, and urinary tract issues. Additionally, it provides antipyretic analgesics, cold medications, gynecological therapies, and anti-infective drugs. Founded in 1995, the firm's headquarters are situated in Guiyang, China.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA, underva

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 09:30

Sam Altman "took the scam to a whole new level": Musk comments on Apple's lawsuit against OpenAI

14.07.2026 08:30

Disney's decision to abandon streaming will boost its stock by 40% — Wells Fargo

14.07.2026 07:30

Jefferies recommended buying shares of Hoka's parent company. The brand could replicate UGG's success.

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026